

Laura Lk Keller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3251049/publications.pdf>

Version: 2024-02-01

23
papers

1,557
citations

430874

18
h-index

677142

22
g-index

25
all docs

25
docs citations

25
times ranked

2631
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 159-179.	3.3	30
2	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. <i>Cancer Research</i> , 2022, 82, 349-358.	0.9	57
3	Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer. <i>Clinical Chemistry</i> , 2022, 68, 973-983.	3.2	2
4	Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. <i>British Journal of Cancer</i> , 2021, 124, 345-358.	6.4	238
5	Nanobody-Based Quantification of GTP-Bound RHO Conformation Reveals RHOA and RHOC Activation Independent from Their Total Expression in Breast Cancer. <i>Analytical Chemistry</i> , 2021, 93, 6104-6111.	6.5	4
6	Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100817.	6.4	49
7	Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray Platform. <i>Advanced Biology</i> , 2020, 4, 1900162.	3.0	19
8	Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!. <i>Cells</i> , 2020, 9, 2486.	4.1	16
9	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 20-31.	3.0	19
10	Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. <i>Cancers</i> , 2019, 11, 1685.	3.7	23
11	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2019, 19, 553-567.	28.4	393
12	Selection and Characterization of a Nanobody Biosensor of GTP-Bound RHO Activities. <i>Antibodies</i> , 2019, 8, 8.	2.5	26
13	A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective toward the Cellular RHOβ GTP-Bound Conformation. <i>Cell Chemical Biology</i> , 2019, 26, 1544-1558.e6.	5.2	32
14	Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 1-6.	2.0	79
15	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. <i>Acta Dermato-Venereologica</i> , 2019, 99, 206-210.	1.3	22
16	Biology and clinical relevance of EpCAM. <i>Cell Stress</i> , 2019, 3, 165-180.	3.2	127
17	Abstract 3985: Dynamic changes of tumor-derived extracellular vesicles and related RNAs in blood samples of NSCLC patients. , 2019, , .		0
18	Monitoring of <i>KRAS</i> -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 38056-38060.	1.8	71

#	ARTICLE	IF	CITATIONS
19	NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. <i>ELife</i> , 2016, 5, .	6.0	231
20	Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF -Mutated Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, e109-e112.	1.1	27
21	Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS -mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2016, 100, 1-4.	2.0	53
22	RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. <i>Breast Cancer Research</i> , 2013, 15, R6.	5.0	32
23	A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective Towards the Cellular RHOB GTP-Bound Conformation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1